LivaNova reports Q1 adjusted EPS 88c, consensus 76c

Reports Q1 revenue $316.9M, consensus $302.37M. “In the first quarter, LivaNova (LIVN) delivered solid revenue growth, driven by the ongoing success of the Essenz rollout, deman1d for Cardiopulmonary consumables, and strong Neuromodulation performance in the Europe and Rest of World regions,” said Vladimir Makatsaria, CEO. “This top-line result, coupled with operational efficiencies, contributed to meaningful operating income growth and cash generation. Importantly, we also achieved significant regulatory and clinical milestones in our obstructive sleep apnea program, including our PMA submission and 12-month data from the OSPREY trial. These achievements reflect effective execution across the organization and reinforce our focus on talent, innovation, growth, and operational excellence.”